Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study
International Journal of Hematology · 2025-02 · 121 (2) · 161-173
DOI: 10.1007/s12185-024-03875-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Hematology, online erschienen am 26.11.2024. Verfasst von Tsuyoshi Muta und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine Clinical Laboratory, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Adenine, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical K.K..
Abstract (Originalsprache)
Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor that is approved for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in Japan based on randomized clinical trial data. The aim of the real-world, retrospective Orbit study was to describe long-term clinical outcomes and management in adults (aged ≥ 20 years) with CLL/SLL treated with ibrutinib, either as first-line (1L) treatment or for relapsed or refractory (RR) disease, in routine clinical practice in Japan between July 2018 and December 2020. A total of 246 patients were registered, and the safety and per-protocol sets included 237 and 234 patients, respectively. After a median follow-up of 35.7 months, the 36-month progression-free survival rate was 80.9% in the 1L CLL cohort and 67.2% in the RR CLL cohort, and the 36-month overall survival rates were 90.8% and 83.7%, respectively. Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3 adverse events of special interest were atrial fibrillation (2.1%), infections (herpesvirus infection, fungal infection, or Pneumocystis jiroveci pneumonia; 1.7%), bleeding (3.8%), and second primary malignancy (2.5%). These findings confirm the long-term, real-world effectiveness and safety of ibrutinib for the treatment of Japanese patients with newly diagnosed or RR CLL/SLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Medicine Clinical Laboratory, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
- Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Hematology, Toranomon Hospital, Tokyo, Japan.
- Department of Hematology and Oncology, Toyohashi Municipal Hospital, Aichi, Japan.
- Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine and Faculty of Medicine, Akita, Japan.
- Department of Hematology, Akita Red Cross Hospital, Akita, Japan.
Förderung
- Janssen Pharmaceutical K.K.
Zitieren
APA
Muta, T., Masamoto, Y., Yamamoto, G., Kurahashi, S., Kameoka, Y., Ota, S., Matsuki, E., Ozeki, K., Toyama, T., Takahashi, N., Kumode, T., Aotsuka, N., Yoshimura, T., Tamura, H., Omi, A., Shibayama, K., Watanabe, A., Isobe, Y., Kojima, K., …, & Aoki, S. (2025). Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study. International Journal of Hematology, 121(2), 161-173. https://doi.org/10.1007/s12185-024-03875-0
Vancouver
Muta T, Masamoto Y, Yamamoto G, Kurahashi S, Kameoka Y, Ota S, et al. Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study. International Journal of Hematology. 2025;121(2):161-173. doi:10.1007/s12185-024-03875-0
BibTeX
@article{Muta2025,
author = {Muta, Tsuyoshi and Masamoto, Yosuke and Yamamoto, Go and Kurahashi, Shingo and Kameoka, Yoshihiro and Ota, Shuichi and Matsuki, Eri and Ozeki, Kazutaka and Toyama, Takanori and Takahashi, Naoki and Kumode, Takahiro and Aotsuka, Nobuyuki and Yoshimura, Takuro and Tamura, Hideto and Omi, Ai and Shibayama, Kazuhiro and Watanabe, Aki and Isobe, Yasushi and Kojima, Kensuke and Takizawa, Jun and Nagai, Hirokazu and Suzumiya, Junji and Aoki, Sadao},
title = {Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study},
journal = {International Journal of Hematology},
year = {2025},
volume = {121},
number = {2},
pages = {161--173},
doi = {10.1007/s12185-024-03875-0}
}
EUVIMED